BPA for lupkynis
Ended Awarded Last action
- Contract number
- 36E79721A0019
- Awardee
-
Aurinia Pharma US Inc. UEI Y394MPDW6GH4
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $7,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement to Aurinia Pharma US Inc. on August 3, 2021, for the supply of Lupkynis (voclosporin), an immunosuppressant medication approved by the Food and Drug Administration for the treatment of lupus nephritis. The contract carries a ceiling value of $7,000,000.00 and extends through August 2, 2026, with no small business set-aside applied. This BPA was established to provide a streamlined procurement mechanism enabling Veterans Affairs medical facilities nationwide to order Lupkynis for eligible veteran patients without requiring individual competitive solicitations for each purchase requirement. The contract leverages Aurinia's existing GSA Schedule contract for Pharmaceuticals and Drugs (Federal Supply Schedule 61-IB), which serves as the master contract vehicle under which this BPA operates.
Under this agreement, Aurinia Pharma US Inc. functions as the sole source provider of Lupkynis for the Department of Veterans Affairs, ensuring consistent supply chain access to this specialized immunosuppressive therapy for veterans diagnosed with lupus nephritis. The BPA structure allows VA facilities flexibility in ordering quantities and timing of deliveries according to clinical demand while maintaining the negotiated pricing established at contract award. This procurement approach reflects the government's recognition of Aurinia as the sole manufacturer of this recently approved therapeutic agent, and the BPA model reduces administrative burden on VA medical centers by pre-establishing the terms and conditions for a five-year period rather than requiring repetitive competitive procurement actions for each individual medication order.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79721A0019?
36E79721A0019 was awarded to Aurinia Pharma US Inc. by National Acquisition Center (Headquarters) on August 3, 2021.
How much is contract 36E79721A0019 worth?
36E79721A0019's own ceiling is $7,000,000.
Who can order from contract 36E79721A0019?
36E79721A0019 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79721A0019 under another contract?
Yes. 36E79721A0019 is a blanket purchase agreement under 36F79721D0217, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79721A0019 competed?
The extent of competition for 36E79721A0019 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV